Belite Bio develops tinlarebant, a daily pill for two causes of vision loss, Stargardt disease and geographic atrophy; FDA is reviewing it for Stargardt, and it is not approved anywhere.
Tinlarebant lowers RBP4 to reduce toxic by-products in the retina. In DRAGON, a Phase 3 in 104 adolescents with Stargardt disease, it slowed lesion growth 35.7% versus placebo over two years. FDA accepted the NDA with Priority Review and a February 12, 2027 decision date; Japan and three Access Consortium countries are also reviewing it. No Stargardt treatment is approved anywhere. Cash and U.S. Treasuries of $780 million fund the launch.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA approves tinlarebant
Does FDA approve tinlarebant for Stargardt disease on the DRAGON data?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Tinlarebant's Stargardt disease NDA has a February 12, 2027 FDA decision date
First-ever STGD1 therapy filing at FDA with a clean Phase 3 win — approval in February 2027 is the single make-or-break event
Tinlarebant's NDA for adolescent Stargardt disease hinges on FDA acceptance and approval after a Phase 3 primary endpoint met with 35.7% lesion growth reduction
Tinlarebant's NDA under FDA review for adolescent STGD1 — approval hinges on whether Phase 3 lesion growth data satisfies regulatory bar for a disease with no approved treatment
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Tinlarebant
Disease areas: Eye diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.